Laboratory studies have shown that nasal drugs are expected to slow the progression of Parkinson's disease

A potential new treatment for Parkinson's disease developed by researchers at Rush University Medical Center has succeeded in slowing the progression of the disease in mice

In a study published in Nature Communications, Rush’s researchers found that two different peptides (amino acid chains) help slow the spread of synuclein

"Currently, there are no treatments to slow the progression of Parkinson's disease-they only treat symptoms," Rush University Medical Center Floyd A.

Lewy bodies are also associated with the development of Lewy body dementia and a rare neurological disease, multiple system atrophy (MSA)

In this study, the peptides developed in the laboratory are called the tlr2 interaction domain (TIDM) and nemo binding domain (NBD) of Myd88

Pahan said: "If these results can be replicated in patients, this will be a significant advancement in the treatment of destructive neurological disorders

This research was funded by the National Institutes of Health

DOI

10.

Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo